Tissue polypeptide antigen (TPA) in comparison with mutations of tumour suppressor gene p53 (TP53) in patients with bladder cancer

Anticancer Research

Volumn 23, Issue 2 A, 2003, Pages 957-962

  Ecke, Thorsten H ^a   Lenk, Severin V ^b   Schlechte, Horst H ^b   Loening, Stefan A ^b  

^a Department of Urology   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Bladder cancer; Mutation; p53; Tissue polypeptide antigen; TPA; Tumour marker; Tumour suppressor gene

Indexed keywords

PROTEIN P53; TISSUE POLYPEPTIDE ANTIGEN;

ADULT; BLADDER CARCINOMA; CONFERENCE PAPER; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GEL ELECTROPHORESIS; GENE AMPLIFICATION; GENE EXPRESSION; GENE MUTATION; GENETIC ANALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SUPERFICIAL CANCER; TUMOR SUPPRESSOR GENE;

APOPTOSIS; CELL DIVISION; EXONS; GENES, P53; HUMANS; LUMINESCENT MEASUREMENTS; MUTATION; NEOPLASM INVASIVENESS; POLYMERASE CHAIN REACTION; REFERENCE VALUES; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; TISSUE POLYPEPTIDE ANTIGEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; URINARY BLADDER NEOPLASMS; UROLOGIC DISEASES;

EID: 0037861921     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (33)

1. Björklund B and Björklund V: Antigenicity of pooled human malignant and normal tissues by cito-immunological technique: presence of an insoluble, heatlabile tumor antigen. Int Arch Allergy 10: 153-84, 1957.
2. Björklund B: On the nature and clinical use of tissue polypeptide antigen (TPA). Tumor Diagnostik 1: 9-20, 1980.
3. Bodey B and Kaiser HE: Immunophenotypically heterogenous cell subpopulations in primary and metastatic human melanomas (Meeting abstract). Anticancer Res 15: 1789, 1995.
4. Casetta G, Piana P, Cavallini A, Vottero M and Tizzani A: Urinary levels of tumour associated antigens (CA 19-9, TPA and CEA) in patients with neoplastic and non-neoplastic urothelial abnormalities. Brit J Urol 72: 60-64, 1993.
5. Correale M, Arnberg H, Blockx P, Bombardieri E, Castelli M, Encabo, G, Gion M, Klapdo R, Martin M, Nilsson S, Reutgen H, Ruggieri G, Safi F, StegmUller M and Vering A: Clinical profile of a new antibody-based immunoassay for tissue polypeptide antigen. Int J Biol Markers 9: 231-238, 1994.
6. Dittadi R, Coradini D, Meo S, Pirronello E, Daidone MG and Gion M: Tissue polypeptide antigen as a putative indicator of apoptosis. Clin Chem 44: 2002-2003, 1998.
7. Esrig D, Elmajian D, Groshen S et al.: Accumulation of p53 and tumor progression in bladder cancer. N Engl J Med 331: 1259-1264, 1994.
8. Filella X, Menendez V, Molina R, Alcover J, Carretero P and Ballesta AM: TPA prognostic value in superficial bladder cancer. Anticancer Res 16: 2173-2176, 1996.
9. Fischer LN, Carbin BE, Bdcklander M, Lanneskog AC and Sundström B: A standardized protocol for determination of TPA in urine by a monoclonal assay and its clinical significance. Sangtec Medical, Bromma, Sweden.
10. Harris CC: P53: At the crossroads of molecular carcinogenesis and risk assessment. Science 262: 1980-1, 1993.
11. Harris CC: Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer 88: 1442-55, 1996.
12. Kirsch J, Oehr P and Winkler C: Localization of tissue polypeptide antigen in interphase HeLa cells by immunofluorescence microscopy. Tumor Diagnostik & Therapie 4: 222-4, 1983.
13. Kroft SH and Oyasu R: Biology of disease; urinary bladder cancer: mechanisms of development and progression. Lab Invest 71: 158-74, 1994.
14. Kuczyk MA, Serth J, Bokemeyer C, Hervatin C, Oelke M, Oelert F, Hbfner K and Jonas U: Wertigkeit von proliferationsstatus (PCNA) und p53-immunhistochemie als prognosefaktor ftir den klinischen verlauf superfizieller harnblasenkarzinome. Urologe 34: 146-152, 1995.
15. Lowe SW, Schmitt SW, Smith SW, Osborne BA and Jacks T: p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature 362: 847-9, 1993.
16. Maulard C, Toubert ME, Chretien Y, Delanian S, Dufour B and Housset M: Serum tissue polypeptide antigen (s-TPA) in bladder cancer as a tumour marker. A prospective study. Cancer 73: 394-398, 1994.
17. McBride OW, Merry D and Givol D: The gene for human p53 cellular tumor antigen is located on chromosome 17 short arm (17p13). Proc Natl Acad Sci USA 83: 130-4, 1986.
18. Miller C, Mohandas T, Wolf D, Prokocimer M, Rotter V and Koeffler HP: Human p53 localized to short arm of chromosome 17. Nature 319:783-4, 1986.
19. Moch H, Sauter G, Mihatsch MJ et al.: p53 but not erbB-2 expression is associated with rapid tumor proliferation in urinary bladder cancer. Human Pathology 25: 1346-1350, 1994.
20. Moraglio D, Pagano M, Galeazzi D, Arnelli A and Bertero L: Tissue polypeptide specific antigen (TPS) in liver disease. Clin Chim Acta 224: 209-214, 1994.
21. Nathrath WBJ and Heidenkummer P: Lokalisation von "Tissue-Polypeptide-Antigen" (TPA) in normalen und neoplastischen Geweben des Menschen. Verh Dtsch Ges Path 67: 701, 1983.
22. Nathrath WBJ, Heidenkummer P, Björklund V and Björklund B: Distribution of tissue polypeptide antigen (TPA) in normal human tissues: immunohistochemical study on unfixed, methanol-, ethanol-, and formalin-fixed tissues. J Histochem Cytochem 33(2): 99-109, 1985.
23. Oehr P, Vogel J, Bellmann O, Rick C and Hlawatsch B: Zusammenhang zwischen plasma- und gewebenachweis von TPA und CEA beim mammakarzinom. Verh Dtsch Ges Path 70: 473, 1986.
24. Ozbun MA and Butel JS: p53 tumor suppressor gene: structure and function. In: Encyclopedia of Cancer, Volume II, Academic Press 1997; pp 1240-1257.
25. Sdnchez-Carbayo M, Herrero E, Megias J, Mira A and Soria F: Comparative sensitivity of urinary CYFRA 21-1, urinary bladder cancer antigen and NMP22 to detect bladder cancer. J Urol 162: 1951-1956, 1999.
26. Serth J, Kuczyk MA, Bokemeyer C et al.: p53 immunohistochemistry as an independent prognostic factor for superficial transitional cell carcinoma of the bladder. Brit J Cancer 71: 201-205, 1995.
27. Silen A, Wiklund B, Andersson EL and Nilsson S: A novel IRMA and ELISA for quantifying cytokeratin 8 and 18 fragments in the sera of healthy individuals and cancer patients. Scand J Clin Lab Invest 55(2): 153-61, 1995.
28. Schlechte HH, Schnorr D, Loening T, Rudolph BD, Pohrt UM and Loening SA: Mutation of the tumor suppressor gene p53 in human prostate and bladder cancers-investigation by Temperature Gradient Gel Electrophoresis (TGGE). J Urol 157: 1049-53, 1997.
29. Sidransky D and Hollstein M: Clinical implications of the p53 gene. Ann Rev Med 47: 285-301, 1996.
30. Spruck III CH, Rideot III WM, Olumi AF, Ohneseit PF, Yang AS, Tsai YC, Nichols PW, Horn T, Hermann GG, Steven K, Ross RK, Yu MC and Jones PA: Distinct pattern of p53 mutations in bladder cancer: Relationship to tobacco usage. Cancer Res 53: 1162-1166, 1993.
31. Stieber P, Schmeller N, Schambeck C, Hofmann K, Reiter W, Hasholzner U and Fateh-Moghadam A: Clinical relevance of CYFRA 21-1, TPA-IRMA and TPA-LIA-mat in urinary bladder cancer. Anticancer Res 16: 3753-3758, 1996.
32. Symonds H, Krall L, Remington L, Saenz-Robles M, Lowe S, Jacks T and Van Dyke T: p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-11, 1994.
33. van Engeland M, Kuijpers JH, Ramaekers FCS, Reutelingsperger CPM and Schutte B: Plasma membrane alterations and cytoskeletal. changes in apoptosis. Exptl Cell Res 235: 421-430, 1997.